Selective inhibitors of cyclooxygenase 2 – their past, present and future

1. Ghlichloo I., Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). StatPearls Publishing 2022.

2. Ahn G.Y., Bae S.-C. Strategies for the safe use of non-steroidal anti-inflammatory drugs. J. Korean. Med. Assoc. 2018; 61, 367–375. https://doi.org/10.5124/jkma.2018.61.6.367

3. Bindu S., Mazumder S., Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol. 2020; 180, 114147. https://doi.org/10.1016/j.bcp.2020.114147

4. Fortune business insights. Non-steroidal Anti-Inflammatory Drugs [NSAIDs] Market Size By 2027 n.d. https://www.fortunebusinessinsights.com/non-steroidal--anti-inflammatory-drugs-nsaids-market-102823 (30. 6. 2022).

5. Kasciuškevičiūtė S., Gumbrevičius G., Vendzelytė A., Ščiupokas A., Petrikonis K., Kaduševičius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. Medicina 2018; 54, 30. https://doi.org/10.3390/medicina540200306. OECD. Health at a Glance 2021 - OECD n.d. https://www.oecd.org/health/health-at-a-glance/ (30. 6. 2022).

7. NCZI. Zdravotnícka ročenka Slovenskej republiky 2021. Spotreba_liekov_a_zdravotnickych_pomocok_v_SR_2021_Sprava_k_publikovanym_vystupom.pdf (nczisk.sk)

8. Gažová A., Kyselovič J. Známe a neznáme fakty o diklofenaku. Via practica 2017; 14(6), 311–312. www.solen.sk

9. Lukáč J., Lukáčová O. Účinnosť a bezpečnosť koxibov. Ambulantná terapia 2007; 5(3–4), 192–198.

10. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol. 1971; 231, 232–235. https://doi.org/10.1038/newbio231232a0

11. Rouzer C. A., Marnett L. J. Cyclooxygenases: structural and functional insights. J. Lipid Res. 2009; 50, S29–34. https://doi.org/10.1194/jlr.R800042-JLR200

12. Domper Arnal M.-J., Hijos-Mallada G., Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin. Drug Saf. 2022; 21, 373–384. https://doi.org/10.1080/14740338.2021.1965988

13. Ju Z., Li M., Xu J., Howell D. C., Li Z., Chen F.-E. Recent development on COX-2 inhibitors as promising antiinflammatory agents: The past 10 years. Acta Pharm. Sin. B. 2022; 12, 2790–2807. https://doi.org/10.1016/j.apsb.2022.01.002

14. Ahmadi M., Bekeschus S., Weltmann K.-D., von Woedtke T., Wende K. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med. Chem. 2022; 13, 471–496. https://doi.org/10.1039/D1MD00280E

15. Szeto C.-C., Sugano K., Wang J.-G., Fujimoto K., Whittle S., Modi G. K., Chen C. H., Park J. B., Tam L. S., Vareesangthip K., Tsoi K. K. F., Chan F. K. L. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut 2020; 69, 617–29. https://doi.org/10.1136/gutjnl-2019-319300

16. Masferrer J., Zweifel B., Manning P., Hauser S., Leahy K., Smith W., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994; 91, 3228–3232. https://doi.org/10.1073/pnas.91.8.3228

17. Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F., Burr A. M., Zhao W. W., Kent J. D., Lefkowith J. B., Verburg K. M., Geis G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284, 1247–1255. https://doi.org/10.1001/jama.284.10.1247

18. Malhotra S., Shafiq N., Pandhi P. COX-2 Inhibitors: A CLASS Act or Just VIGORously Promoted. MedGenMed2004; 6, 6.

19. MERCK & CO.,INC. VIOXX®, Warning: Risk of serious cardiovascular and gastrointestinal events. www.accessdata.fda.gov, 2016.

20. Lenzer J. FDA is incapable of protecting US “against another Vioxx.” BMJ 2004; 329, 1253.

21. Research C for DE and. Vioxx (rofecoxib) Questions and Answers. FDA 2018.

22. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171, 1027–1028. https://doi.org/10.1503/cmaj.1041606

23. Heerdink E. R., Leufkens H. G., Herings R. M., Ottervanger J. P., Stricker B. H., Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med. 1998; 158, 1108–1112. https://doi.org/10.1001/archinte.158.10.1108

24. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. The Lancet 2004; 364, 1995–1996. https://doi.org/10.1016/S0140-6736(04)17523-5

25. EMA.www.ema.europa.eu/en/documents/referral/rofecoxib-article-31-referral-annex-i-ii-iii_en.pdf

26. El-Malah A. A., Gineinah M. M., Deb P. K., Khayyat A. N., Bansal M., Venugopala K. N., Aljahdali A. S. Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals 2022; 15, 827. https://doi.org/10.3390/ph15070827

27. Schnitzer T. J., Burmester G. R., Mysler E., Hochberg M. C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C. J.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364, 665–674. https://doi.org/10.1016/S0140-6736(04)16893-1

28. Reed G. W., Nissen S. E. NSAID choice: lessons from PRECISION. Aging (Albany NY) 2019; 11, 2181–2182. https://doi.org/10.18632/aging.101930

29. Inova Health Care Services. NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease. clinicaltrials.gov; 2018.

30. Kitov Pharma Ltd. A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy. clinicaltrials.gov; 2019.

31. Chen W., Zhong Y., Feng N., Guo Z., Wang S., Xing D. New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases. Mol. Med. 2021; 27, 123. https://doi.org/10.1186/s10020-021-00358-4